Právní předpis byl sestaven k datu 19.12.2013.
Zobrazené znění právního předpisu je účinné od 25.12.2012 do 19.12.2013.
97
SDĚLENÍ
Xxxxxxxxxxxx zahraničních xxxx,
xxxxxx se mění x xxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx xxxx x. 58/2007 Sb. x. x., č. 46/2008 Xx. x. x. x x. 47/2012 Sb. x. x. x Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx sportu
Xxxxxxxxxxxx xxxxxxxxxxxx xxxx xxxxxxx, xx xxx 16. listopadu 2011 xxxx xxxxxxxxx ředitelkou XXXXXX oznámeno xxxxxxxxx xxxxxx znění Xxxxxxx X - Xxxxxxx xxxxxxxxxx xxxxx x xxxxx - Mezinárodní xxxxxxxx Xxxxxxxxxxx xxxxxx xxxxx dopingu ve xxxxxx.1)
S novým xxxxxx Xxxxxxx I xxxxxxxx xxxxxxx Parlament Xxxxx xxxxxxxxx.
Nové xxxxx Xxxxxxx X xxxxxxxxx x platnost x xxxxxxx x xxxxxxx 34 odst. 3 Xxxxxx dne 1. ledna 2012 x tímto xxxx xxxxxxxxx v xxxxxxxx x xxx Českou xxxxxxxxx. Xxxx vstupu xxxxxx znění Přílohy X x xxxxxxxx xxxxxxxx xxxxxx xxxxx Xxxxxxx I Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx sportu platné xx 1. xxxxx 2011 x xxxxxxxxx xxx č. 47/2012 Sb. m. s.
Anglické xxxxx Xxxxxxx X x její xxxxxxx xx českého xxxxxx xx xxxxxxxxx xxxxxxxx.
1) Xxxxxxxxxxx xxxxxx proti xxxxxxx xx xxxxxx přijatá xxx 19. října 2005 v Xxxxxx xxxx xxxxxxxxx pod č. 58/2007 Sb. m. s.
XXXXXXXXXXX XXXXXX XXXXX XXXXXXX XX XXXXXX
Xxxxxxx X - Xxxxxx xxxxxxxxxx xxxxx a xxxxx - Mezinárodní xxxxxxxx
Paříž, 1. xxxxx 2012
XXXXXX XXXXXXXXXX XXXXX A XXXXX DOPINGU XXX XXX 2012
XXXXXXX XXXXXXXXXXXXX XXXXX
Xxxxxx xx 1. ledna 2012
Xxxxx xxxxxx 4.2.2 Xxxxxxxxx antidopingového xxxxxx xxxxxxx Xxxxxxxx xxxxx budou považovány xx "Xxxxxxxxxx xxxxx" xxxxx xxxxx xx xxxxxx S1, X2, X4.4, S4.5 x X6(x) x Xxxxxxxxxx xxxxx M1, X2 x X3.
LÁTKY X METODY XXXXXXXX XXXXX (PŘI XXXXXXX X XXXX XXXXXX) |
XXXXXXXX XXXXX
S0. XXXXXXXXXXX XXXXX
Xxxxxxxxx xxxxxxxxxxxxx xxxxx, xxxxx xxxx zahrnuta v xxxxxxxxxxxxx xxxxxxx Xxxxxxx x xxxx xxxxxxxx xxxxxxxxx pro humánní xxxxxxxxxxxx xxxxxxx jakýmkoliv xxxxxxx zdravotnickým xxxxxxxxxx xxxxxx (např. léčiva x preklinickém xxxx xxxxxxxxx xxxxxx výzkumu xxxx xx xxxxxxxx xxxxxxxxxx, xxxxxxxxxx xxxxx, xxxxxxxxxxx xxxx), xx xxxxxxxx stále.
S1. XXXXXXXXXX LÁTKY
Anabolické xxxxx xxxx zakázány.
1. XXXXXXXXXX ANABOLICKÉ XXXXXXXX (XXX):
(a) Xxxxxxxx* XXX, xxxxxxxxxx:
1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3β,17β-xxxx); 1-androstendion (5α-xxxxxxx-1-xx-3,17-xxxx); xxxxxxxxx (estr-4-en-3β,17β-diol); xxxxxxxxxx; xxxxxxxx; xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx); xxxxxxx (17α-xxxxxxx-17β-xxxxxxxxxxxxxx-4-xxx[2,3-x]xxxxxxxx); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17β-xx); xxxxxxxxxxx; ethylestrenol (19-xxx-17α-xxxxx-4-xx-17-xx); fluoxymesteron; xxxxxxxxxx; xxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxxxxx[2,3-x]-xxxxxxx); xxxxxxxxx; 4-xxxxxxxxxxxxxxxxxx (4,17β-dihydroxyandrost-4-en-3-on); kalusteron; xxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxx; xxxxxxxxxxx; metasteron (2α, 17α-xxxxxxxx-5α-xxxxxxxxx-3-xx-17β-xx); methyldienolon (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx); xxxxxx-1-xxxxxxxxxxx (17β-hydroxy-17α-methyl-5α-androst-1-en-3-on); methylnortestosteron (17β-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx); xxxxxxxxxxxxxxxxx; xxxxxxxxxx (xxxxxxxxxxxxxxx (17β-hydroxy-17α-methylestra-4,9,11-trien-3-on); miboleron; xxxxxxxxx; 19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx); xxxxxxxxxx; xxxxxxxxxxxxxx; norklostebol; xxxxxxxx; oxandrolon; xxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-hydroxy-5α-androstano [3,2-x]xxxxxxx); xxxxxxxxx; xxxxxxxxxx; xxxxxxxxx; 1-testosteron (17β-xxxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxx (18α-xxxx-xxxxxx-4,9,11-xxxxx-17β-xx-3-xx); trenbolon x další látky x podobnou xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
(x) Xxxxxxxxx** XXX, xxxxx xxxx xxxxxx xxxxxxxx:
Xxxxxxxxxxxxx (androst-5-en-3β,17β-diol), xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx), xxxxxxxxxxxxxxxxxx, xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, XXXX), xxxxxxxxxxx x jejich xxxxxxxxxx x xxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx:
5α-xxxxxxxxx-3α,17α-xxxx | 5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx) |
5α-xxxxxxxxx-3α,17β-xxxx | |
5α-xxxxxxxxx-3β,17α-xxxx | xxx-xxxxxxxxxxxxxxxxxx |
5α-xxxxxxxxx-3β,17β-xxxx | xxxxxxxxxxxxxx |
xxxxxxx-4-xx-3α,17α-xxxx | 3α-xxxxxxx-5αxxxxxxxxx-17-xx |
xxxxxxx-4-xx-3α,17β-xxxx | 3β-xxxxxxx-5αxxxxxxxxx-17-xx |
xxxxxxx-5-xx-3β,17α-xxxx | 7α-xxxxxxx-XXXX |
xxxxxxx-5-xx-3α,17α-xxxx | 7β-xxxxxxx-XXXX |
androst-5-en-3α,17β-dioI | 7-xxxx-XXXX |
xxxxxxx-5-xx-3β,17α-xxxx | 19-norandrosteron |
4-xxxxxxxxxxxxx (androst-4-en-3β,17β-diol) | 19-xxxxxxxxxxxxxxxxx |
2. Ostatní anabolické xxxxx, zahrnující:
Xxxxxxxxxxx, xxxxxxxxxx xxxxxxxxxx androgenových xxxxxxxxx (XXXX), tibolon, xxxxxxx, xxxxxxxxxx, xxx xx x omezením xxxxx na xx.
Xxx xxxxx xxxxxxx xxxx xxxxx: * "xxxxxxxx" xx xxxxxxxx x látce, kterou xxxx není xxxxxxxx xxxxxxx xxxxxxxxxx přirozeně. ** "endogenní " xx xxxxxxxx x xxxxx, xxxxxx xxxx xxxx xxxxxxxxxx xxxxxxxxx. |
S2. PEPTIDOVÉ XXXXXXX, XXXXXXX XXXXXXX X XXXXXXXX XXXXX
Xxxxxxxxxxx látky x xxxxxx uvolňující xxxxxxx xxxx xxxxxxxx:
1. Xxxxx xxxxxxxxxxx xxxxxxxxxxx (xxxx. xxxxxxxxxxxx (EPO), xxxxxxxxxxx (xXXX), xxxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx faktoru (XXX), xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX), peginesatid /Hematide/);
2. Choriogonadotropin (XX) x Xxxxxxxxxxxx hormon (XX) x mužů;
3. Xxxxxxxx;
4. Xxxxxxxxxxxxxx;
5. Xxxxxxx xxxxxx (XX), xxxxxxxxxxxxx xxxxxxx faktory (XXXx), xxxxxxxxxxxx růstový xxxxxx (XXX), xxxxxxxx podobný xxxxxxx faktor-1 (IGF-1), xxxxxxxxxx růstové xxxxxxx (XXX), xxxxxxx xxxxxx xxxxxxxx x xxxxxxxx xxxxxxxx (XXXX) x xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (XXXX), xxxxxx xxxx xxxxxxxxx xxxx růstové xxxxxxx ovlivňující syntézu xxxx xxxxxxxxx xxxxxxxx xxxxx, šlach x xxxxxx, xxxxxx xxxxxxxx, xxxxxxx xxxxxxx, regenerativní xxxxxxxx nebo xxxxxxxxxxx xxxx svalových xxxxxx;
x další xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx.
X3. XXXX2- AGONISTÉ
Všichni xxxx-2 xxxxxxxx (xxxxxx xxxx xxxxxxxxxx xxxxxxxxx xxxxxxx) jsou xxxxxxxx xxxxx xxxxxxxxxxx (maximálně 1600 xxxxxxxxxx za 24 hodin), xxxxxxxxxxx (xxxxxxxxx 36 mikrogramů xx 24 hodin) x xxxxxxxxxxx xxxxx xxxx xxxxxx v xxxxxxxx x xxxxxxx x xxxxxxxxxxx xxxxxxxx xxxxxxx výrobce.
Xxxxxxxxxx xxxxxxxxxxx x moči x xxxxxxxxxxx vyšší xxx 1000 xx/xx x xxxxxxxxxx xxxxxxxxxxx x moči x xxxxxxxxxxx vyšší než 30 xx/xx nebude xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxxx použití, xxx xxxx xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxx nález, xxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx farmakokinetickou xxxxxx, xx xxxxxxxxxx výsledek xxx způsoben užíváním xxxxxxxxxxxx xxxxxxxxx xxxxx xxxxx než xxxx xxxxxxx xxxxxxx.
X4. XXXXXXXXX A XXXXXXXXXXX XXXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
1. Xxxxxxxxxx xxxxxxxx, xxxxxxxxxx:
Xxxxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (androstatriendion), 4-xxxxxxxxx-3,6,17-xxxxx (6-xxx),xxxxxxxxx, xxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxx xx x xxxxxxxx xxxxx na xx.
2. Xxxxxxxxxx modulátory xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxxxxx:
Raloxifen, tamoxifen, xxxxxxxxx, ale xx x xxxxxxxx pouze xx xx.
3. Xxxxxxx xxxxxxxxxxxxxx xxxxx xxxxxxxxxx:
Xxxxxxxxxx, fulvestrant, xxxxxxxx, xxx ne x omezením pouze xx ně.
4. Xxxxx modifikující xxxxxx xxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxx, ale xx x xxxxxxxx xxxxx xx xx.
5. Xxxxxxxxxxx modulátory: Xxxxxxxx xxxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxx /Xxxxxxxxxx Xxxxxxxxxxxx Xxxxxxxxx Xxxxxxxx δ (XXXXδ) xxxxxxxx/ (xxxx. GW 1516) x Xxxxxxxx xxxxxxxxxxxxxxx xxx aktivované XXX x xxxxxxxxxxx x XXXX delta /XXXXδ-XXX-xxxxxxxxx xxxxxxx xxxxxx (AMPK) xxxx xxxxxxxx/ (xxxx. XXXXX)
X5. XXXXXXXXX X OSTATNÍ MASKOVACÍ XXXXX
Xxxxxxxxx xxxxx xxxx xxxxxxxx. Xxxxxxxx:
Xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxxxxx (xxxx. xxxxxxxx, xxxxxxxxxx xxxxxx albuminu, xxxxxxxx, xxxxxxxxxxxxxxxxxx x xxxxxxxxx), xxxxxxxxxx x xxxxx xxxxx x podobnými xxxxxxxxxxxx účinky. Lokální xxxxxxxx felypressinu pro xxxxx xxxxxxxx xxxx xxxxxxxx.
Xxxxxxxxx xxxxxxxx:
Xxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxx, xxxxxxxx, xxxxxxxx xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx, thiazidy (xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx), xxxxxxxxxx a xxxxx xxxxx s xxxxxxxx xxxxxxxxx strukturou xxxx podobnými biologickými xxxxxx (xxxxx xxxxxxxxxxxx, xxxxxxxxx x lokálního xxxxxx xxxxxxxxxxx x xxxxxxxxxxxx, xxxxx xxxxxx xxxxxxxx).
Xxx použití (Xxx Soutěži, xxxxxxxx Xxxx Xxxxxx) xxxxxxxxxxx xxxxxxxx látky xx xxxxxxxxxx xxxxxxxx xxxxxxx (xx. xxxxxxxxxx, xxxxxxxxxx, xxxxxx, xxxxx, xxxxxxx, xxxxxxxxxxxx a xxxxxxxxxxxxx) xx spojení x xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxxx xx xxxxxxxxxx xxxxxxx xxxxxxxxxx Xxxxxxxxxxxx xxxxxxx xx xxxx látku xxxxx x xx, která xxx xxxx udělena xx xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxx.
XXXXXXXX XXXXXX
M1. XXXXXXXXX XXXXXXX XXXXXXX
Xxxxxxxx je xxxxxxxxxxx:
1. Xxxxxx xxxxxx, xxxxxx xxxxxxx xxxxxxxxx, xxxxxxxxx xxxx heterologní xxxx nebo xxxxxxxxx xxxxxxx a jim xxxxxxxxx produktů xxxxxxxxxxx xxxxxx.
2. Umělé xxxxxxxxx xxxxxxxx, xxxxxxx xxxx xxxxxxx kyslíku, xxxxxxxxxx modifikované xxxxxxxxxxxxx xxxxxxxx (xxxx.xxxxxx náhražky xxxxxxxx xx hemoglobinu, xxxxxxxxxxxxxxxxxx hemoglobiny), xxxxxxxxxxxxxxxxxxx x xxxxxxxxxxx (XXX13), xxx xx x xxxxxxxx xxxxx na xx. Xxxxxxxx xxxxxxx xxxxxxxx xxxx.
M2. XXXXXXXX X FYZIKÁLNÍ XXXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
1. Xxxxxxxxx, xxxx pokus x xxxxxx, xx xxxxxx xxxxxxx xxxxxxxxx x xxxxxxxx Xxxxxx xxxxxxxxxx xxx Xxxxxxxxx kontrole xx xxxxxxxx. Xx xxxxxxxx xxxxxx x/xxxx xxxxxx (xxxx. proteázami) xxxx, xxx xx x xxxxxxxx xxxxx xx xx.
2. Xxxxxxxxxx infuze x/xxxx xxxxxxx více xxx 50 ml xx 6 xxxxx xxxx xxxxxxxx xxxxx xxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxx xxxxxxxxxxxx xxxxxxx xxxx xxxxxxxxxx vyšetřovacích xxxxx.
3. Xxxxxxxx xxxxx, xxxxxxxxxx x xxxxxxxxx jakéhokoliv xxxxxxxx xxxx xxxx do xxxxxxxxx xxxxxxx je xxxxxxxx.
X3. GENOVÝ XXXXXX
X xxxxxx xxxxxxxxxx xx xxxxxxx xxxxxxxxxxx výkonu je xxxxxxxx následující:
1. Xxxxxxxx nukleových kyselin xxxx xxxxxx xxxxxxxx;
2. Xxxxxxx xxxxxxxxxx xxxx geneticky xxxxxxxxxxxxxx xxxxx;
XXXXX X XXXXXX ZAKÁZANÉ XXX XXXXXXX |
Xxxxx xxxxxxxxx SO xx S5 x X1 xx X3 xxxxxxxxx xxxx xxxx Xxx Xxxxxxx xxxxxxxx x xxxxxxxxxxx xxxxxxx:
XXXXXXXX LÁTKY
X6. XXXXXXXXXXX
Xxxxxxx xxxxxxxxxxx (xxxxxx xxxx jejich xxxxxxxxxx optických isomerů) xxxx xxxxxxxx, x xxxxxxxx xxxxxxxx imidazoiu x xxxxxxx xxxxxx xxxxxxxx xxxxxxx x xxxxxxxxxxx xxxxxxxxxx do Xxxxxxxxxxxxxx xxxxxxxx pro xxx 2012*.
Xxxxxxxxxxx xxxxxxxx:
(x) Nespecifická xxxxxxxxxxx:
Xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxxxxx, ethylamfetamin, xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, fenmetrazin, xxxxxxxxxxx, fentermin, 4-fenylpiracetam (xxxxxxxx), xxxxxxxxxx, xxxxxxxxxxx, xxxxxx, xxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, metamfetamin (x-), xxxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxx, x-xxxxxxxxxxxxxxx, xxxxxxxxxx, prolintan.
Xxxxxxxxxxxx, xxxxx xxxx xxxxxxxx uvedeno v xxxxx xxxxxxxx, je Xxxxxxxxxxx xxxxxx.
(x) Xxxxxxxxxx stimulancia (xxxxxxxx):
Xxxxxxxxx**, xxxxx***, xxxxxxx****, xxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, heptaminol, xxxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxx****, xxxxxxxxxxxxx, xxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxx), xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, oxilofrin, parahydroxyamfetamin, xxxxxxx, pentetrazol, xxxxxxxxxxxxxx, xxxxxxxxxxxxx*****xxxxxxxxx, sibutramin, xxxxxxxxx, xxxxxxxxxxxxx a xxxxx xxxxx s xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
* Xxxxxxxxxxx xxxxx xxxxxxxx xx Monitorovacího xxxxxxxx 2012 (bupropion, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, kofein, xxxxxxx, xxxxxxxxx, synefrin) xxxxxx xxxxxxxxxx za Xxxxxxxx xxxxx.
** Xxxxxxx podání adrenalinu (xxxx. nosní, xxxx xxxxxxxx) xxxx jeho xxxxxx xxxxxxxx s xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxx.
*** Xxxxx xx xxxxxxxx pouze xxx xxxxxxxxxxx xxxxx xxx 5 mikrogramů x 1 xx xxxx.
**** Efedrin x xxxxxxxxxxxxx jsou xxxxxxxx xxx xxxxxxxxxxx xxxxx než 10 xxxxxxxxxx x 1 xx xxxx.
***** Xxxxxxxxxxxxx je xxxxxxx, xxxxx jeho xxxxxxxxxxx x moči xx xxxxx než 150 xxxxxxxxxx xx xxxxxxxx
X7. NARKOTIKA
Xxxxxxxx xx následujíci:
Xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx(xxxxxx), xxxxxxxx x xxxx deriváty, xxxxxxxxxxx, xxxxxxx, xxxxxx, xxxxxxxx, oxymorfon, xxxxxxxxxx, xxxxxxx.
S8. KANABINOIDY
Xxxxxxxx (xxxx. hašiš, xxxxxx x xxxxxxxxx) xxxx syntetický xxxxx9xxxxxxxxxxxxxxxxxxx (XXX) x xxxxxxxxxxxxxx (xxxx. "Xxxxx" /obsahující XXX018, XXX073/ x XX-210) xxxx zakázané.
X9. GLUKOKORTIKOSTEROIDY
Xxxxxxx xxxxxxxxxxxxxxxxxxxx xxxxxxxx orálně, xxxxxxxx, xxxxxxxxxx nebo xxxxxxxxxxxxx aplikací jsou xxxxxxxx.
XXXXX XXXXXXXX X URČITÝCH XXXXXXXX |
X1. XXXXXXX
Xxxxxxx (xxxxxx) xx xxxxxxxx pouze Xxx Soutěži v xxxxxxxxxxxxx sportech. Detekce xx xxxx xxxxxxxx xxxxxxxx xxxxxxxx x/xxxx xxxxxxxx xxxx. Xxxxxxx xxxxxxx xxx porušeni xxxxxxxxxxx xxxxxxxx (xxxxxxxxxxxxx xxxxxxx) xx 0.10 x/x.
∙ Automobilový xxxxx (XXX)
∙ Xxxxxx (XXX)
∙ Xxxxxxx sporty a xxxxxxxxxxxx(XXX)
∙ Lukostřelba (XXXX)
∙ Xxxxxxxxxxx xxxxx (FIM)
∙ Xxxxx xxxxxxxxxx (XXX)
X2. BETA-BLOKÁTORY
Pokud xxxx xxxxx určeno, xxxx-xxxxxxxxx jsou zakázány xxxxx Xxx Xxxxxxx x následujících xxxxxxxx.
∙ Xxxxxxxxxxxx xxxxx (XXX)
∙ Xxxxxxxx (xxxxxxx xxxxxxxxxx) (XXXX)
∙ Xxxxx (XXX)
∙ Golf (IGF)
∙ Xxxxxxx x xxxxxxx (FIQ)
∙ Xxxxxxx sporty x xxxxxxxxxxxx (XXX)
∙ Xxxxxxxxxxx (FITA, XXX) (xxxxxxxx xxxx Xxxx xxxxxx)
∙ Xxxxxxxx (XXX) - xxxxx xx xxxxxx x xxxxxxxxxxx xxxxxxxx-xxxxx x X-xxxxx,x xxxxxxxxx X-xxxxx x "xxx xxx"
∙ Xxxxxxxx x xxxxxxx sporty (XXXX)
∙ Xxxxxxx (XXXX, XXX) (zakázané xxxx Xxxx xxxxxx)
∙ Xxxxx (XXX)
∙ Xxxxx xxxxxxxxxx (XxX)
Xxxx-xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxx:
Xxxxxxxxxx, alprenolol, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxx, karvedilol, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxx, xxxxxxx, xxx ne s xxxxxxxx xxxxx xx xx.
Xxxxxxxxx
Xxxxxx předpis x. 97/2012 Xx. m. x. xxxxx xxxxxxxxx xxxx 25.12.2012.
Xxxxxx předpis x. 97/2012 Xx. x. x. xxx xxxxxx xxxxxxx xxxxxxxxx č. 98/2013 Sb. m. s. x účinností od 20.12.2013.
Znění xxxxxxxxxxxx xxxxxxxx norem xxxxxx xxxxxxxx předpisů x xxxxxxxx xxxx xxxxxxxxxxxxx, pokud se xxxx netýká derogační xxxxx xxxxx uvedeného xxxxxxxx xxxxxxxx.